Malignant pleural mesothelioma clinical trials, like other clinical trials, can help to prevent, screen for, and treat the disease. They also provide a point of reference for future research. Participating in a clinical trial gives trial participants access to health care advancements that otherwise may be unavailable to them.

Mesothelioma arises most commonly from exposure to asbestos particles that build up in the lungs to cause health problems later. Usually, it takes 20 to 40 years for mesothelioma to develop after asbestos exposure. Variability in disease presentation is one challenging aspect of malignant pleural mesothelioma, in addition to its rare, aggressive, and fatal nature.

Why Clinical Trials Matter

These trials matter because they work to improve disease prevention, screening, and treatment. The trials are typically controlled studies of people, testing a new intervention for safety, effectiveness, and side effects. Clinical trials are often run by cancer centers, government agencies, and pharmaceutical companies. Each trial follows strict guidelines to study its specific objectives. A well-defined protocol helps the researchers identify if the intervention is beneficial and the need for further study. 

Why Participate in a Clinical Trial

An individual may decide to participate in a mesothelioma clinical trial because it allows them to receive some of the best possible treatment. Even if the treatment does not benefit a particular individual, the research could help others or even find a cure for malignant pleural mesothelioma.

Participant Recruitment

Dozens of mesothelioma clinical trials are currently taking place. Some of the most noteworthy trials focus on 

• Chimeric Antigen Receptor (CAR) T-Cell Therapy¹
• Durvalumab and Tremelimumab²
• Keytruda and Anetumab Ravtansine³

All of these clinical trials have shown promise in the treatment of mesothelioma. 

Most commonly, patients enroll in a trial at the recommendation of their doctor. Doctors can provide their patients with background information and identify which clinical trials best fit their needs and values. Specialists within medical oncology are an excellent resource for a second opinion, helping a patient weigh the risks and benefits of participating in a clinical trial.